Position in CBUS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$432,291
+$341,178 QoQ
Shares Held
218,329
+316.9% QoQ
Ownership
0.286%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CBUS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GOLDMAN SACHS GROUP INC holds $13,181,249,908 across 360 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,481,761 | $1,232,765,138 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,163,191 | $725,296,113 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
18,556,458 | $656,713,046 | |
| 4 | TECH |
BIO-TECHNE Corp
|
7,343,324 | $518,805,838 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
2,133,101 | $399,487,154 | |
| 6 | MRNA |
Moderna, Inc.
|
4,671,950 | $327,176,656 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
9,980,620 | $311,994,180 | |
| 8 | INCY |
Incyte Corp
|
2,305,782 | $261,383,446 |
All Filings in CBUS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $432,291 | 218,329 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $91,113 | 52,364 | Shares | Defined | 2026-03-25 | |
| 2025-09-30 | $42,114 | 32,647 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $123,087 | 89,194 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $90,647 | 48,475 | Shares | Defined | 2025-06-27 | |
| 2024-12-31 | $197,018 | 70,870 | Shares | Defined | 2025-02-11 | |
| 2024-09-30 | $135,912 | 41,691 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $853,758 | 86,676 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $2,153,644 | 95,888 | Shares | Defined | 2024-05-15 | |
| 2023-09-30 | $262,349 | 14,399 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||